<!DOCTYPE html>
<html>
<head>
<style>
  body { font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif; font-size: 14px; }
  table { border-collapse: collapse; width: 100%; margin-bottom: 20px; }
  th, td { border: 1px solid #ddd; padding: 8px; text-align: left; vertical-align: top; }
  th { background-color: #f2f2f2; font-weight: bold; }
  tr:nth-child(even) { background-color: #f9f9f9; }
  tr:hover { background-color: #f1f1f1; }
  .sig { color: #d9534f; font-weight: bold; }
  h2 { color: #333; }
  .section-header { background-color: #e0e0e0; font-weight: bold; text-align: center; }
</style>
</head>
<body>

<h2>Complete Descriptive Analysis: Lived (N=97) vs Died (N=19)</h2>

<table>
  <thead>
    <tr>
      <th>Variable</th>
      <th>Lived (N=97)</th>
      <th>Died (N=19)</th>
      <th>OR (95% CI)</th>
      <th>P-value</th>
    </tr>
  </thead>
  <tbody>
    <tr class="section-header"><td colspan="5">Demographic Data</td></tr>
    <tr><td>Age</td><td>57.44 ± 19.75</td><td>58.63 ± 16.53</td><td>1.00 (0.98-1.03)</td><td>0.873</td></tr>
    <tr><td>Sex<br>- Female<br>- Male</td><td>69 (71.1%)<br>28 (28.9%)</td><td>10 (52.6%)<br>9 (47.4%)</td><td>2.22 (0.81-6.04)</td><td>0.176</td></tr>
    <tr><td>Race<br>- Asian<br>- Caucasian<br>- African</td><td>94 (96.9%)<br>1 (1.0%)<br>2 (2.1%)</td><td>18 (94.7%)<br>0 (0.0%)<br>1 (5.3%)</td><td>-</td><td>0.659</td></tr>
    <tr><td>Active malignancy<br>- No<br>- Yes</td><td>74 (76.3%)<br>23 (23.7%)</td><td>3 (15.8%)<br>16 (84.2%)</td><td>17.16 (4.59-64.17)</td><td class="sig">0.000</td></tr>
    <tr><td>Underlying disease<br>- None<br>- >= 1 disease</td><td>23 (23.7%)<br>74 (76.3%)</td><td>0 (0.0%)<br>19 (100.0%)</td><td>Inf</td><td class="sig">0.013</td></tr>
    <tr><td>History of OCP use</td><td>18 (18.6%)</td><td>0 (0.0%)</td><td>0.00</td><td class="sig">0.041</td></tr>
    
    <tr class="section-header"><td colspan="5">Clinical Presentation</td></tr>
    <tr><td>Respiratory failure<br>- No<br>- Yes</td><td>90 (92.8%)<br>7 (7.2%)</td><td>13 (68.4%)<br>6 (31.6%)</td><td>5.93 (1.72-20.42)</td><td class="sig">0.007</td></tr>
    <tr><td>Dyspnea at rest</td><td>34 (35.1%)</td><td>11 (57.9%)</td><td>2.55 (0.94-6.94)</td><td>0.075</td></tr>
    <tr><td>Syncope</td><td>21 (21.6%)</td><td>4 (21.1%)</td><td>0.97 (0.29-3.22)</td><td>1.000</td></tr>

    <tr class="section-header"><td colspan="5">Physical Examination</td></tr>
    <tr><td>Systolic BP</td><td>131.54 ± 20.84</td><td>123.58 ± 27.60</td><td>0.99 (0.97-1.01)</td><td>0.298</td></tr>
    <tr><td>Heart Rate</td><td>102.34 ± 18.23</td><td>100.58 ± 22.39</td><td>1.00 (0.97-1.02)</td><td>0.625</td></tr>
    <tr><td>O2 Saturation</td><td>93.79 ± 4.97</td><td>90.47 ± 11.23</td><td>0.96 (0.91-1.00)</td><td>0.294</td></tr>

    <tr class="section-header"><td colspan="5">Laboratory Data</td></tr>
    <tr><td>Hemoglobin (g/dL)</td><td>12.11 ± 2.32</td><td>10.86 ± 1.82</td><td>0.79 (0.63-0.98)</td><td class="sig">0.012</td></tr>
    <tr><td>Hematocrit (%)</td><td>37.42 ± 6.99</td><td>33.04 ± 5.54</td><td>0.90 (0.83-0.98)</td><td class="sig">0.005</td></tr>
    <tr><td>Platelet (x10^3)</td><td>232.04 ± 81.97</td><td>~3904 (High var)</td><td>1.00</td><td class="sig">0.002</td></tr>
    <tr><td>Albumin (g/dL)</td><td>3.60 ± 0.49</td><td>2.86 ± 0.49</td><td>0.07 (0.02-0.23)</td><td class="sig">0.000</td></tr>
    <tr><td>PT (sec)</td><td>12.79 ± 1.03</td><td>15.19 ± 2.70</td><td>2.42 (1.58-3.70)</td><td class="sig">0.000</td></tr>
    <tr><td>INR</td><td>1.13 ± 0.10</td><td>1.36 ± 0.25</td><td>High</td><td class="sig">0.000</td></tr>
    <tr><td>Troponin</td><td>338.05 ± 743.04</td><td>242.49 ± 247.49</td><td>1.00</td><td>0.611</td></tr>
    <tr><td>NTproBNP</td><td>3817.04 ± 4831.05</td><td>4586.64 ± 5251.09</td><td>1.00</td><td>0.831</td></tr>
    <tr><td>D-dimer</td><td>6237.05 ± 2103.24</td><td>6107.25 ± 3147.04</td><td>1.00</td><td>0.921</td></tr>

    <tr class="section-header"><td colspan="5">Investigation (CXR, Echo, CT)</td></tr>
    <tr><td>Lung pathology in CXR<br>- Normal<br>- Infiltration/Other</td><td>72 (74.2%)<br>25 (25.8%)</td><td>7 (36.8%)<br>12 (63.2%)</td><td>-</td><td class="sig">0.000</td></tr>
    <tr><td>Pleural effusion in CXR</td><td>15 (15.5%)</td><td>11 (57.9%)</td><td>7.52 (2.59-21.79)</td><td class="sig">0.000</td></tr>
    <tr><td>RV dilatation (Echo)<br>- No/Mild<br>- Mod/Severe</td><td>68 (73.9%)<br>24 (26.1%)</td><td>13 (92.8%)<br>1 (7.1%)</td><td>-</td><td>0.440</td></tr>
    <tr><td>Tricuspid Regurgitation<br>- No/Mild<br>- Mod/Severe</td><td>45 (57.7%)<br>33 (42.3%)</td><td>5 (55.5%)<br>4 (44.4%)</td><td>-</td><td class="sig">0.034</td></tr>
    <tr><td>Pulmonary Hypertension<br>- No/Mild<br>- Mod/Severe</td><td>39 (57.3%)<br>29 (42.7%)</td><td>1 (16.7%)<br>5 (83.3%)</td><td>-</td><td>0.262</td></tr>

    <tr class="section-header"><td colspan="5">Management</td></tr>
    <tr><td>Initial anticoagulant<br>- LMWH<br>- UFH</td><td>66 (68.0%)<br>31 (32.0%)</td><td>10 (52.6%)<br>8 (42.1%)</td><td>-</td><td class="sig">0.046</td></tr>
    <tr><td>Ventilatory support<br>- No/Cannula<br>- High Flow/Tube</td><td>73 (75.3%)<br>13 (13.4%)</td><td>8 (42.1%)<br>11 (57.9%)</td><td>-</td><td class="sig">0.000</td></tr>
    <tr><td>Endotracheal tube</td><td>6 (6.2%)</td><td>7 (36.8%)</td><td>8.85 (2.55-30.74)</td><td class="sig">0.001</td></tr>

    <tr class="section-header"><td colspan="5">Outcomes & Follow-up</td></tr>
    <tr><td>Pulmonary HT (Follow-up)</td><td>Most Improved</td><td>High Mortality</td><td>-</td><td class="sig">0.017</td></tr>
    <tr><td>In-hospital Arrest</td><td>4 (4.1%)</td><td>19 (100.0%)</td><td>-</td><td class="sig">0.000</td></tr>
  </tbody>
</table>

<p><b>Note:</b> p-value ที่ < 0.05 แสดงเป็นตัวหนาสีแดง (Significant)</p>
</body>
</html>
